Two scientists share 2018 Nobel Prize in Physiology or Medicine

Adjust Comment Print

Allison, an American immunologist, conducted a study on a protein that functions as a brake on the immune system.

Cancer immunotherapy is extremely effective for a substantial minority of patients, potentially adding years to their lives and even curing some people. He identified CTLA-4 as an inhibitory receptor of T-cells and pioneering the development of immune checkpoint inhibitors for the treatment of a range of cancers.

The first of this year's Nobel Prizes, in medicine, was awarded Monday to cancer researchers James P. Allison and Tasuku Honjo.

As The Guardian explains, the human immune system "normally seeks out and destroys mutated cells, but cancer finds sophisticated ways to hide from immune attacks", in part by "ramping up braking mechanisms created to prevent immune cells from attacking normal tissue".

"It is all about interference with the brakes of our immune system as a means to unleash this defense and harness it to develop treatment of cancer", said Klas Karre, an immunologist at Sweden's Karolinska Institute and a member of the Nobel committee, after the announcement in Stockholm this morning.

"I want to continue my research... so that this immune therapy will save more cancer patients than ever", he told reporters at the University of Kyoto where he is based.

Tasuku Honjo, a professor at Japan's Kyoto University, said winning the prize was "a great honor".

Japan’s strongest typhoon in 25 years Jebi wrecks havoc
Television footage showed waves pounding the coastline, sheet metal tumbling across a vehicle park and a truck turned on its side. Japan is regularly hit by powerful typhoons in the summer and autumn, many of which cause flooding and landslides in rural areas.

This drug, dubbed ipilimumab - sold as Yervoy - was approved by the US Food and Drug Administration for the treatment of melanoma in 2011 and is also undergoing trials for use in lung, bladder and prostate cancer.

After taking various drugs and other options and finding no relief, Shimizu finally tried the newly-developed Opdivo. In cancer the patient's immune system becomes weak and is not able to fight against tumor but the latest medicine will enable patients to strengthen and fight cancer through their own body mechanisms.

The two scientists will share the 9 million-Swedish-kronor ($1 million) prize. Born on August 7, 1948, Dr Allison's discoveries have led to breakthroughs in the treatment of the deadliest of cancers. 10 Facts About Cancer You Need to Know by World Health Organization (WHO).

Allison said: "I'm honoured and humbled to receive this prestigious recognition".

Medicine is normally the first of the Nobel Prizes awarded each year. Dr. Allison is chairman of the department of immunology at the University of Texas and has spent his career developing strategies for cancer immunotherapy. Honojo's lab discovered when they injected antibodies against PD-1 that cancer cells could no longer dupe the T-cells.

"I never dreamed my research would take the direction it has", he said in a statement on his university's website.

Tasuku Honjo, the other recipient of a 2018 Nobel for Medicine, also researched immune system brakes.